论文部分内容阅读
据WHO报道,全球约20亿人曾感染过乙型病毒性肝炎病毒(HBV),约3.5亿人为慢性HBV感染者[1]。我国现有约2000万慢性乙型病毒性肝炎(chronic hepatitis B,CHB)患者[2]。慢性HBV的炎症和纤维化准确分期一直是评估严重程度和临床治疗的重要依据[3]。由于扩散加权成像(DWI)无创、安全、快捷,对肝脏炎症及纤维化程度评价敏感性和特异性较高,因此有望部分替代肝脏穿刺活检用于肝脏炎症
According to the WHO, about 2 billion people worldwide have been infected with hepatitis B virus (HBV) and about 350 million people with chronic HBV infection [1]. There are about 20 million patients with chronic hepatitis B (CHB) in China [2]. Accurate staging of inflammation and fibrosis in chronic HBV has been an important basis for assessing the severity and clinical management [3]. Because diffusion-weighted imaging (DWI) is noninvasive, safe and rapid and has high sensitivity and specificity for the evaluation of liver inflammation and fibrosis, it is expected that partial replacement of liver biopsy for liver inflammation